Global Short Bowel Syndrome (SBS) Market to Grow at a CAGR of 25.5% by 2021 - Key Vendors are Emmaus Medical, Merck & Shire - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Short Bowel Syndrome (SBS) Market 2017-2021" report to their offering.

The global short bowel syndrome (SBS) market to grow at a CAGR of 25.53% during the period 2017-2021.

The report, Global Short Bowel Syndrome (SBS) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is increased awareness of GI disorders. Pharmaceutical companies and national and local government bodies such as the health ministry and municipalities are conducting programs to spread awareness of GI disorders. Many NGOs also conduct camps to educate people and raise the awareness level. Drug manufacturers supply visual aids or free samples to physicians and sometimes to individuals to spread awareness of the disorders and promote their drugs. This is done to increase the knowledge of the individuals about a particular GI disorder.

According to the report, one of the major drivers for this market is special drug designations. As the market is dominated by a few drugs and the pipeline also demonstrates the same, the special designation will provide more opportunity for revenue generation and to expand geographically. These designations carry benefits such as an extension of patent exclusivity period to address the need for an orphan drug, tax credits of up to 50% of R&D costs, and orphan drug's sponsors are exempted from paying the US FDA application fees. These benefits will reduce the burden from vendors to develop a product for a rare disease.

Key vendors

  • Emmaus Medical
  • Merck
  • Shire

Other prominent vendors

  • Ardelyx
  • Naia Pharmaceuticals
  • Nutrinia
  • OxThera
  • Sancilio Pharmaceuticals
  • Zealand Pharma

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Orphan drug designation

PART 06: Pipeline landscape

PART 07: Market landscape

PART 08: Market segmentation by route of administration (ROA)

PART 09: Market segmentation by drug class

PART 10: Geographical segmentation

PART 11: Decision framework

PART 12: Drivers and challenges

PART 13: Market trends

PART 14: Vendor landscape

PART 15: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/gzn9gm/global_short

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs